Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: A meta-epidemiological study.

Da Costa, B. R.; Saadat, P.; Basciani, R. M.; Agarwal, A.; Johnston, B. C.; Jüni, P. (2021). Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: A meta-epidemiological study. Osteoarthritis and cartilage, 29(3), pp. 304-312. Elsevier 10.1016/j.joca.2020.10.004

Text daCosta_OsteoarthritisCartilage_2021.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

OBJECTIVE

To compare assay sensitivity of the Visual Analogue Scale (VAS) for global osteoarthritis pain and the Western Ontario and McMaster University (WOMAC) pain subscale, and the associated between-trial heterogeneity in effect sizes (ES).

DESIGN

We included trials with placebo, sham or non-intervention control that included at least 100 patients with hip or knee osteoarthritis per arm, reporting both VAS and WOMAC pain scores. ES were calculated as between-group difference in means divided by the pooled standard deviation and compared using a paired t-test. ES and τ2 as a measure of between-trial heterogeneity were combined using random-effects meta-regression with robust variance estimation to account for the correlation of data within trials and meta-analyses.

RESULTS

Twenty-eight trials with 44 randomized comparisons were included. In 28 comparisons (64%), ES from VAS favoured the intervention more than those from WOMAC pain (P=0.003). Twenty-six p-values (59%) were smaller according to VAS (P=0.008). The 44 comparisons contributed to 12 meta-analyses. Eleven meta-analyses (92%) showed larger benefits of interventions according to VAS, with a combined overall difference in ES of -0.08 (95% CI -0.14 to -0.02). τ2 was similar for VAS and WOMAC pain (difference in τ2, -0.003, 95% CI -0.009 to 0.004).

CONCLUSION

The VAS for global pain had slightly higher assay sensitivity at trial and meta-analysis levels than the WOMAC pain subscale without relevant increase in between-trial heterogeneity.

Interest & Impact

Downloads

2 since deposited on 10 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item